| HOME >> BIOLOGY >> TECHNOLOGY |
QUEBEC CITY, July 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has achieved additional positive results with its vaccine candidate for the Influenza A (H1N1) virus, also known as Swine flu. Results showed that a single dose of 5 micrograms induced a positive immune response against a new emerging strain of this virus in 100% of vaccinated animals.
Medicago's H1N1 VLP vaccine was formulated to protect against the influenza A/California/04/09 virus ("California/04"), which was one of the original viral strains selected by the WHO for vaccine manufacturers. The Company previously reported data from an initial study in mice where its novel vaccine achieved a positive immune response in 100% of the animals vaccinated against the California/04 virus. In a continuation of this study, Medicago tested the immune response of its H1N1 vaccine against the California/07 virus, a more current and mutated strain and showed positive immune response after a single dose of 5 micrograms. The challenge of current pandemic influenza vaccines is they have to match the circulating strain in order to be effective.
"We have already demonstrated the speed of our technology by producing an H1N1 vaccine candidate and initiating animal testing while other vaccine manufacturers were still waiting for a seed strain from the WHO. These additional data expand upon the results we announced in June and support our belief that our influenza vaccines are also capable of providing protection against different circulating viral strains," said Andy Sheldon, President and CEO of Medicago. "Unlike current vaccine manufacturers that have experienced difficulties producing a pandemic candidate for H1N1, our H1N1 vaccine candidate was well expressed in our plant-based system and has produc
'/>"/>
| SOURCE Medicago Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
2. Vical Presentation at Military Pandemic Influenza Workshop
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. NASA technology helps predict and prevent future pandemic outbreaks
5. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
6. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
7. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
8. H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria
9. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
10. CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans
11. Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |